Amicis Research Center

1. AstraZeneca Pharmaceuticals LP $3,502,243 85 payments
2. AstraZeneca UK Limited $3,494,442 32 payments
3. CSL Behring $980,440 287 payments
4. Cleerly, Inc. $781,956 68 payments
5. GlaxoSmithKline, LLC. $780,013 97 payments
6. Boehringer Ingelheim International GmbH $602,106 332 payments
7. Horizon Therapeutics plc $507,920 8 payments
8. Alnylam Pharmaceuticals Inc. $458,056 129 payments
9. Eli Lilly and Company $359,239 9 payments
10. Sumitomo Pharma America, Inc. $358,916 32 payments

1. A Phase 2b multicentre randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of zibotentan and dapagliflozin in patients with chronic kidney disease with estimated glomerular filtration rate eGFR between 20 and 60 mL min 1.73 m2 $2,680,887 18 payments
2. A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $1,453,815 12 payments
3. A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease $970,467 16 payments
4. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $844,982 10 payments
5. Transform $781,956 68 payments
6. EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $621,428 330 payments
7. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $569,570 176 payments
8. A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease $410,870 111 payments
9. Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $368,209 42 payments
10. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $347,651 3 payments

1. Other $76,913 24 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.